Announcements Trials

Browse Landscape

Phase

Phase 2 27 Phase 3 3 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 16 Thoracic 4 Lymphoid 3 CNS 2 Breast 2 Tumor-Agnostic 1 Sarcoma 1 Other solid neoplasm 1 Head & Neck 1

Conditions

Head and Neck Neoplasms 1

Interventions

pembrolizumab 65 Cisplatin 42 Cetuximab 36 Radiotherapy 28 Nivolumab 26 Paclitaxel 22 Carboplatin 22 Docetaxel 20 durvalumab 14 Radiotherapy, Intensity-Modulated 12 Fluorouracil 12 Cyclophosphamide 11 tremelimumab 9 Gemcitabine 9 Ipilimumab 8 fludarabine 7 avelumab 7 Erlotinib Hydrochloride 7 toripalimab 6 epacadostat 6 cemiplimab 6 Radiosurgery 6 Interleukin-2 6 Capecitabine 6 Bevacizumab 6 spartalizumab 5 Celecoxib 5 zalutumumab 4 tislelizumab 4 fludarabine phosphate 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × apatinib × Head & Neck × Clear all

NCT03654612 2018-10-18

Y-HR2017-025

China International Medical Foundation

Phase 1/2 Unknown

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡